Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer 2023, 13: 235-245. PMID: 38756146, PMCID: PMC11095597, DOI: 10.1159/000533991.Peer-Reviewed Original ResearchChild-Pugh class B patientsChild-Pugh B patientsClass B patientsObjective response rateProgression-free survivalChild-Pugh AB patientsOverall survivalHepatocellular carcinomaAdverse eventsLiver functionOdds ratioChild-Pugh class A patientsTreatment-related adverse eventsChild-Pugh class AHigher objective response rateShorter progression-free survivalMedian overall survivalAlbumin-bilirubin gradeImpaired liver functionClass A patientsUnresectable hepatocellular carcinomaIndividualization of treatmentChild-PughALBI grade